Management of MM at Early Relapse

 

Penn Medicine Abramson Cancer Center
D

New Therapies for Relapsed Myeloma

By Penn Medicine Abramson Cancer Center FEATURING Dan Vogl
By Penn Medicine Abramson Cancer Center FEATURING Dan Vogl
364 views
May 2, 2022
0 Comments
Login to view comments. Click here to Login
Management of MM at Early Relapse
11:29
ASCO 2022 Conference Coverage

ASCO 2022 on the Addition of Carfilzomib as a Third Agent in Lenalid…

Feat. C. Cerchione
19:48
Penn Medicine Abramson Cancer Center

New Therapies for Relapsed Myeloma

Feat. D. Vogl
23:00
Penn Medicine Abramson Cancer Center

Role of Immunotherapy for Myeloma

Feat. A. Cohen
05:24
ecancer

EHA 2022 CARTBCMA-HCB-01 Study Updates: A Novel CAR T-Cell Therapy T…

Feat. C. Fernandez De Larrea
01:29
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Addition of Carfilzomib as a Thir…

Feat. C. Cerchione
12:23
Jonathan L. Kaufman

ASCO 2022 Highlights of the Hematologic Malignancies - Plasma Cell D…

01:27
Jonathan L. Kaufman

Lecture Summary - ASCO 2022 Highlights of the Hematologic Malignanci…

05:57
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Impact of EPd on HRQoL for Patients With R/R …

Feat. K. Weisel
20:31
Ambuga Badari

Management of Multiple Myeloma in First Relapse

15:14
EHA 2022 Conference Coverage

How I Manage Frontline Multiple Myeloma

Feat. C. Cerchione
05:20
Thomas Martin

Health-Related Quality of Life in R/R MM Treated With Teclistamab, a…

01:22
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Health-Related Quality of Life in R/R MM…

Feat. T. Martin
39:01
EHA 2022 Conference Coverage

Present and Future of Management of Relapsed/Refractory Multiple Mye…

Feat. C. Cerchione
15:54
Paul Richardson

Emerging Strategies in the Management of Relapsed MM

08:21
The Ohio State University - Wexner Medical Center

IMS 2022 on Early, Deep, and Durable Responses, and Low Rates of CRS…

Feat. N. Bumma
11:06
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Sequencing Agents in Early Relapsed MM

Feat. K. Patel
04:00
Winship Cancer Institute - Emory University

Daratumumab With Pomalidomide & Dexamethasone at 1st Relapse in …

Feat. N. Joseph